- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA ® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ...

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. ATG-022 is uniquely positioned in the global landscape, with data supporting ...

For over half a century, Big Oil and the plastics industry, through their trade associations and front groups, have sold the public the false idea that plastics are recyclable. Recycling became the ...

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA ® (pembrolizumab) is MSD's anti-PD-1 therapy. ATG-022 is uniquely positioned in the global landscape, with data supporting ...